Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-01022025-260696
EXTRAORDINARY
PART II-Section 3-Sub-section (i)
PUBLISHED BY AUTHORITY
No. 69]
NEW DELHI, SATURDAY, FEBRUARY 1, 2025/MAGHA 12, 1946
MINISTRY OF FINANCE
(Department of Revenue)
NOTIFICATION
New Delhi, the 1st February, 2025
No. 09/2025-Customs
G.S.R. 102(E). — In exercise of the powers conferred by sub-section (1) of section 25 of the Customs Act,
1962 (52 of 1962), the Central Government, on being satisfied that it is necessary in the public interest so to do,
hereby makes the following further amendments in the notification of the Government of India in the Ministry of
Finance (Department of Revenue) No. 16/2017-Customs, dated the 20th April, 2017, published in the Gazette of
India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R. 394(E), dated the 20th April, 2017,
namely :-
In the said notification, in the TABLE, after serial number 52 and the entries relating thereto, the following
serial numbers and the entries shall be inserted, namely :-
+-----+----------------------------+------------------------------------------+------------------------------------------+
| (1) | (2) | (3) | (4) |
+=====+============================+==========================================+==========================================+
| "53.| Pembrolizumab | Key- PAP 1.0 | MSD Pharmaceuticals |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 54. | Pembrolizumab | KIRAN | MSD Pharmaceuticals |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 55. | Lorlatinib | LorbriquaCare | Pfizer Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 56. | Dacomitinib | DacoCare | Pfizer Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 57. | Inotuzumab Ozogamicin | HemaCare | Pfizer Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 58. | Ribociclib | UMAANG | Novartis Healthcare Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 59. | Dabrafenib | UMAANG | Novartis Healthcare Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 60. | Selumetinib | AstraZeneca Pharma PAP | AstraZeneca Pharma India Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 61. | Benralizumab | AstraZeneca Pharma PAP | AstraZeneca Pharma India Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 62. | Fulvestrant | AstraZeneca Pharma PAP | AstraZeneca Pharma India Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 63. | Acalabrutinib | AstraZeneca Pharma PAP | AstraZeneca Pharma India Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 64. | Olaparib | AstraZeneca Pharma PAP | AstraZeneca Pharma India Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 65. | Amivantamab | Johnson and Johnson PAP | Johnson & Johnson Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 66. | Teclistamab | Johnson and Johnson PAP | Johnson & Johnson Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 67. | Ustekinumab | Johnson and Johnson PAP | Johnson & Johnson Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 68. | Daratumumab | Johnson and Johnson PAP | Johnson & Johnson Pvt. Ltd. |
| | And hyaluronidase-fihj | | |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 69. | Ibrutinib | Johnson and Johnson PAP | Johnson & Johnson Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 70. | Bortezomib | Johnson and Johnson PAP | Johnson & Johnson Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 71. | Daratumumab | Johnson and Johnson PAP | Johnson & Johnson Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 72. | Cetuximab | Rainbow PAP | Merck Specialties Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 73. | Avelumab | My Bavencio Assist Program | Merck Specialties Pvt. Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 74. | Tepotinib | My Tepmetko Patient Access | Merck Specialties Pvt. Ltd. |
| | | Program | |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 75. | Brentuximab Vedotin | Takeda PAP | Takeda Biopharmaceuticals India Pvt. |
| | | | Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 76. | Vedolizumab | Takeda PAP | Takeda Biopharmaceuticals India Pvt. |
| | | | Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 77. | Velaglucerase Alpha | Takeda PAP | Takeda Biopharmaceuticals India Pvt. |
| | | | Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 78. | Agalsidase Alpha | Takeda PAP | Takeda Biopharmaceuticals India Pvt. |
| | | | Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 79. | Idursulphase | Takeda PAP | Takeda Biopharmaceuticals India Pvt. |
| | | | Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 80. | Mepolizumab | GSK Pharmaceuticals Limited | GSK Pharmaceuticals Limited |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 81. | Alectinib | The Blue Tree | Roche Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 82. | Risdiplam Powder | The Blue Tree | Roche Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 83. | Emicizumab | The Blue Tree | Roche Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 84. | Atezolizumab | The Blue Tree | Roche Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 85. | Pertuzumab + | The Blue Tree | Roche Products India Private Ltd. |
| | trastuzumab | | |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 86. | Ocrelizumab | The Blue Tree | Roche Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 87. | Polatuzumab vedotin | The Blue Tree | Roche Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 88. | Faricimab | The Blue Tree | Roche Products India Private Ltd. |
+-----+----------------------------+------------------------------------------+------------------------------------------+
| 89. | Luspatercept | Bristol-Myers Patient Assistance | Bristol-Myers Squibb India Pvt. Ltd. ". |
| | | Program | |
+-----+----------------------------+------------------------------------------+------------------------------------------+
2.
This notification shall come into force on the 2nd day of February, 2025.
[F. No. 334/03/2025-TRU]
AMREETA TITUS, Dy. Secy.
Note: The principal notification No. 16/2017-Customs, dated the 20th April, 2017 was published in the Gazette of
India, Extraordinary, Part II, Section 3, Sub-Section (i), vide number G.S.R. 394(E), dated the 30th June, 2017
and last amended vide notification No. 38/2024-Customs, dated the 23rd July, 2024, published in the Gazette of
India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R. 441(E), dated the 23rd July, 2024.